Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study of the safety, efficacy, and tolerability of ezetimibe (Zetia) in combination with statin therapy for the treatment of elevated LDL cholesterol in HIV-infected subjects

X
Trial Profile

A pilot study of the safety, efficacy, and tolerability of ezetimibe (Zetia) in combination with statin therapy for the treatment of elevated LDL cholesterol in HIV-infected subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Oct 2009 Results published in AIDS.
    • 08 Feb 2009 Results reported at the 16th Conference on Retroviruses and Opportunistic Infections.
    • 08 Feb 2009 Primary endpoint 'Low density lipoprotein cholesterol level' has been met according to results presented at the 16th Conference on Retroviruses and Opportunistic Infections.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top